Top Suppliers:I want be here
Related CAS#:
201530-41-8 1133425-75-8
1266741-05-2 619-67-0
201530-78-1 201530-79-2
554435-83-5 554445-58-8
1395346-28-7 1266741-01-8

201530-41-8

201530-41-8 structure
201530-41-8 structure
  • Name: Deferasirox
  • Chemical Name: deferasirox
  • CAS Number: 201530-41-8
  • Molecular Formula: C21H15N3O4
  • Molecular Weight: 373.362
  • Catalog: API Blood system medication Anti-anemia drug
  • Create Date: 2018-08-29 18:33:35
  • Modify Date: 2024-01-01 19:46:52
  • Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
Name deferasirox
Synonyms ICL-670
Exjade
Deferasirox
Description Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
Related Catalog
In Vitro In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower[1]. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent[2]. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner[3].
In Vivo The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy[3].
Cell Assay Deferasirox is dissolved in DMSO. HL-60 or KG-1 cells are treated with 0, 5, 10, 50 μM of deferasirox for 24 or 48 h, and proliferation is determined by an MTT assay[2].
Animal Admin Mice: Murine leukemia cells are injected subcutaneously into the right flank of mice. Deferasirox is dissolved in distilled water and orally administered at 20 mg/kg until the cumulative dose reaches 300 mg/kg. The mice are observed and weighed daily[3].
References

[1]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45.

[2]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5.

[3]. Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46.
Density 1.4±0.1 g/cm3
Boiling Point 672.1±65.0 °C at 760 mmHg
Melting Point 260-262ºC
Molecular Formula C21H15N3O4
Molecular Weight 373.362
Flash Point 360.3±34.3 °C
Exact Mass 373.106262
PSA 107.95000
LogP 6.43
Vapour Pressure 0.0±2.2 mmHg at 25°C
Index of Refraction 1.699
Storage condition -20°C Freezer
Hazard Codes Xi
HS Code 2933990090
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:201530-41-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 201530-41-8 | Chemsrc address: https://www.chemsrc.com/en/baike/894718.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved